Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Dexmedetomidine alleviates microglial activation of neuropathic pain by modulating miR-23a /PDE10A axis in streptozotocin-induced diabetic mice

Qian Wu¹, Yan Qiao², Jiannan Song³

¹Health Management Center, Wuhan Third Hospital, Wuhan City, Hubei Province, 430074; ²Department of Neurology, 024000; ³Department of Anesthesiology, Chifeng Municipal Hospital, Chifeng City, Inner Mongolia Autonomous Region 024000, China.

For correspondence:- Jiannan Song Email: songjiannan321@163.com Tel:+864768365914

Accepted: 8 March 2021 Published: 31 March 2021

Citation: Wu Q, Qiao Y, Song J. Dexmedetomidine alleviates microglial activation of neuropathic pain by modulating miR-23a /PDE10A axis in streptozotocin-induced diabetic mice. Trop J Pharm Res 2021; 20(3):543-549 doi: 10.4314/tjpr.v20i3.15

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To elaborate the functional role of dexmedetomidine (DEX) in alleviating microglial activation of diabetic neuropathic pain (DNP) and explore the involved signaling pathways.

Methods: The viability of BV-2 cells was measured using a commercial kit. Levels of interleukin 1β (IL-1β) and tumor necrosis factor-α (TNF-α) were measured using commercial ELISA kit. The mRNA target was predicted and confirmed using TargetScan and luciferase assay. Protein expression levels were determined by western blotting. Diabetes was indiced in C57BL/6J mice using streptozotocin (STZ) and antidiabetic parameters evaluated in vivo.

Results: DEX suppressed HG-induced microglial activation in BV-2 cells. The levels of IL-1β and TNF-α increased in HG-treated cells, but this was counteracted following DEX treatment. Phosphorylation of p65 (p-p65) was upregulated in cells treated with HG, while DEX repressed this upregulation. MiR-23a was downregulated in BV-2 cells treated with HG, but upregulated by addition of DEX. MiR-23a mimics repressed the induction of IL-1β and TNF-α levels and expression of p-p65. Results from TargetScan and luciferase assays showed that the 3-untranslated region (UTR) of PDE10A was directly targeted by miR-23a. The in vivo studies showed that miR-23a agomir relieved neuropathic pain and reduced the expressions of PDE10A and p-p65 in STZ-induced diabetic mice, but these effects were aggravated by DEX.

Conclusion: The results show that upregulation of miR-23a, DEX alleviates microglial activation of neuropathic pain and reduces levels of inflammatory factors in STZ-induced diabetic C57BL/6J mice. The underlying mechanism was at least partially mediated by PDE10A.

Keywords: Dexmedetomidine, Microglial activation, Diabetic neuropathic pain, MiR-23a, PDE10A